Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
暂无分享,去创建一个
I. Elyazar | R. Noviyanti | D. Subekti | A. Soebandrio | L. Ekawati | I. Sutanto | N. Goyal | S. Duparc | J. Kleim | L. Tan | Justin A. Green | J. Baird | Krisin Chand | Disala Fernando | A. Satyagraha | Instiaty Instiaty | S. Lardo | Siôn W. Jones | E. Cedar | Chelzie Crenna-Darusallam | K. Rolfe | Ana Martin | Hema Sharma | Maxine Taylor | Inge Sutanto | Amin Soebandrio | Lenny L Ekawati | Rintis Noviyanti | Ari Winasti Satyagraha | Decy Subekti | Yulia Widya Santy | Chelzie Crenna-Darusallam | Instiaty Instiaty | Waras Budiman | Catur Bidik Prasetya | Soroy Lardo | Iqbal Elyazar | Stephan Duparc | Eve Cedar | Katie Rolfe | Disala Fernando | Alessandro Berni | Jörg-Peter Kleim | Kim Fletcher | Lionel K Tan | J Kevin Baird | Yulia Widya Santy | Waras Budiman | Catur Bidik Prasetya | Kim Fletcher | Lenny L. Ekawati | Rintis Noviyanti | Lenny L Ekawati | Siôn Jones | Decy Subekti
[1] R. Price,et al. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis , 2022, medRxiv.
[2] H. Win,et al. Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria , 2021, medRxiv.
[3] M. White,et al. Tafenoquine for the prevention of Plasmodium vivax malaria relapse. , 2021, The Lancet. Microbe.
[4] T. Bousema,et al. Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia Ex Vivo: Potentials and Pitfalls , 2020, Antimicrobial Agents and Chemotherapy.
[5] R. Price,et al. Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis , 2020, The American journal of tropical medicine and hygiene.
[6] A. Bacchieri,et al. Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation , 2019, Scientific Reports.
[7] F. Nosten,et al. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.
[8] W. Monteiro,et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.
[9] N. Goyal,et al. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial , 2018, Antimicrobial Agents and Chemotherapy.
[10] I. Elyazar,et al. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria , 2018, JAMA network open.
[11] R. Price,et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study , 2017, PLoS medicine.
[12] N. Goyal,et al. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects , 2016, Antimicrobial Agents and Chemotherapy.
[13] I. Elyazar,et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia , 2015, BMC Medicine.
[14] R. Price,et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.
[15] David L. Smith,et al. Geographical variation in Plasmodium vivax relapse , 2014, Malaria Journal.
[16] S. Krudsood,et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.
[17] N. Gogtay,et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. , 2013, The Cochrane database of systematic reviews.
[18] E. Tjitra,et al. A Randomized Comparison of Dihydroartemisinin-Piperaquine and Artesunate-Amodiaquine Combined With Primaquine for Radical Treatment of Vivax Malaria in Sumatera, Indonesia , 2013, The Journal of infectious diseases.
[19] I. Elyazar,et al. Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia , 2012, Antimicrobial Agents and Chemotherapy.
[20] Anand P. Patil,et al. Plasmodium vivax Malaria Endemicity in Indonesia in 2010 , 2012, PloS one.
[21] D. Kyle,et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) , 2011, Malaria Journal.
[22] Purnomo,et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. , 2003, The American journal of tropical medicine and hygiene.
[23] K. Rieckmann,et al. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. , 1997, The American journal of tropical medicine and hygiene.
[24] W E Collins,et al. Primaquine resistance in Plasmodium vivax. , 1996, The American journal of tropical medicine and hygiene.
[25] R. J. Dern,et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. , 1955, The Journal of laboratory and clinical medicine.
[26] M. D. Young,et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. , 1950, Journal. National Malaria Society.
[27] Winarno,et al. The distribution and bionomics of anopheles malaria vector mosquitoes in Indonesia. , 2013, Advances in parasitology.